Skip to main content

Rush COVID-19 Research in the News

September 24, 2020

  • Patients with COVID-19 may have higher risk of kidney injury
    ScienceDaily

    According to Jochen Reiser, MD, PhD, the Ralph C Brown MD professor and chairperson of Rush's Department of Internal Medicine, patients with COVID-19 experience elevated levels of soluble urokinase receptor (suPAR), an immune-derived pathogenic protein that is strongly predictive of kidney injury.
     

June 25, 2020

News features on a review of how coughing and sneezing affect respiratory transmission of viruses, coauthored by Jie Li, PhD, RRT, associate professor, Department of Cardiopulmonary Services, Division of Respiratory Care, Rush University Medical Center.
 

June 11, 2020

  • Health care workers at Rush invited to participate in national PCORnet study of hydroxychloroquine
    Science Magazine
    This feature on Rush's Healthcare Worker Exposure Response & Outcomes of Hydroxychloroquine (HERO-HCQ) Trial among health care workers (now closed for enrollment) quotes Yoona Rhee, assistant professor of infectious diseases and the primary investigator of the study.
     

May 22, 2020

May 16, 2020

May 14, 2020

  • Low-Tech Way to Help Some Covid Patients: Flip Them Over
    The New York Times
    This exploration of proning to improve breathing in coronavirus patients quotes Sara Hanif Mirza, MD, MS on Rush's clinical trial of the technique.
  • Study suggests a protein may predict severe COVID-19
    Medical News Today
    Jochen Reiser, MD, PhD, chairman of the Department of Internal Medicine, discusses findings by researchers at Rush University Medical Center and other institutions suggesting that a protein called suPAR could be predictive of which patients with COVID-19 might need breathing support from ventilators.
     

May 12, 2020

May 5, 2020

April 25, 2020

April 22, 2020

  • 'Proning' Is a Promising Treatment for Coronavirus—Here's How It Works
    Health.com
    A look at applications of the proning technique in treating COVID-19 patients, including the clinical trial currently underway at Rush.
     

April 14, 2020

April 10, 2020